Avaí Bio

What Avaí Bio does

Avaí Bio (OTCQB: AVAI) is a publicly traded, pre-revenue biotechnology company headquartered in North Las Vegas, Nevada, that develops genetically modified, encapsulated live-cell therapies targeting diabetes and age-related diseases. The company's pipeline is organized around two 50/50 joint ventures with the Austrianova/SGAustria group: Klothonova LLC (formed September 2025), which advances a genetically modified cell line engineered to overexpress the α-Klotho "longevity protein" for conditions including chronic kidney disease, neurodegenerative disorders, vascular disease, and cardiovascular disease; and Insulinova, Inc. (formed November 2025), which is developing encapsulated insulin-producing cells intended to produce, store, and secrete insulin in response to blood glucose levels as a treatment for type 1 and insulin-dependent type 2 diabetes. Both programs rely on Austrianova's proprietary Cell-in-a-Box® cellulose sulfate encapsulation platform to shield therapeutic cells from immune rejection, remove the requirement for immunosuppression, support continuous protein secretion, and mitigate cell migration and tumor formation risk.

The underlying technical architecture pairs genetically engineered human cell lines—producing ~580 pg of α-Klotho per 1,000 cells per 24 hours (~8,120 pg per capsule per 24 hours)—with the Cell-in-a-Box® encapsulation platform, which is backed by over 50 peer-reviewed publications and is manufactured to GMP standards at Austrianova's Singapore facility. Key executed milestones include GMP Master Cell Bank production completion in May 2026, an exclusive worldwide license from Klothea Bio (November 2025) routed through Klothonova, and a minor diagnostic JV with Ainnova Tech (September 2025) to integrate Vision AI–based disease detection into the platform ecosystem.

The company makes no commercial product revenue today; the business model is structured around joint development and eventual commercialization through the JV entities, supplemented by a non-core Lifestyle Wellness Assessment API (deterministic rule-based). Revenue mechanics, when they materialize, are expected to flow from milestone payments, royalties on net sales, and ultimately FDA-approved encapsulated cell therapy products in specialty pharmacy and hospital channels. The customer base is pre-commercial, and current go-to-market activity is concentrated on licensing, partnership formation, conference presence (EPITA, Klotho Conference), and small-cap public market participation on the OTCQB tier. The entity rebranded from Avant Technologies, Inc. to Avaí Bio, Inc. on February 11, 2026.

Name

Avaí Bio

Legal name

Avaí Bio, Inc.

Website

https://avaibio.com

Company type

Public

Founded year

2026

Operating status

Operating

Short description

Avaí Bio is a publicly traded biotechnology company developing genetically modified, encapsulated cell therapies for type 1 and insulin-dependent type 2 diabetes and age-related diseases through two 50/50 joint ventures—Klothonova (α-Klotho) and Insulinova (insulin-producing cells)—using Austrianova's proprietary Cell-in-a-Box® encapsulation technology.

Ownership category

akta.pro rank

Product category

Cell Therapy Biotechnology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Blood and Organ Banks (621991)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Cell-based therapies
• Encapsulated cell therapy
• Diabetes therapeutics
• Longevity protein therapy
• Regenerative biotechnology

Headquarters

HQ city

North Las Vegas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Cell-based Therapy Development and Commercialization: Pre-revenue biotechnology company. The company is developing two pipeline programs: α-Klotho longevity protein therapy (via Klothonova JV) and diabetes treatment (via Insulinova JV). Revenue potential exists through eventual FDA-approved cell therapy products, though commercial launch timeline is not specified as products remain in preclinical/early clinical development stage.

Go-to-market motion1 record

Marketing channels8 records

Core offering

Avaí Bio is a clinical-stage biotechnology company developing genetically modified, encapsulated cell therapies for diabetes and age-related diseases. The company operates through two joint ventures—Klothonova (α-Klotho longevity protein therapy) and Insulinova (encapsulated insulin-producing cell therapy for diabetes)—leveraging Austrianova's proprietary Cell-in-a-Box® cell encapsulation technology to enable sustained, localized therapeutic protein delivery without requiring immunosuppression.

Product overview

Avaí Bio is a biotechnology company developing cell-based therapies through two main programs: the α-Klotho Development Program (Klothonova) targeting age-related diseases and anti-aging treatments, and the Diabetes Development Program (Insulinova) for type 1 and insulin-dependent type 2 diabetes. Both programs use genetically modified cells combined with Austrianova's Cell-in-a-Box® encapsulation technology to protect therapeutic cells and enable sustained protein delivery. The company also operates a Lifestyle Wellness Assessment API as a supporting wellness service.

Differentiator

Problem solved

Functional benefit

Products and services

• Insulinova Diabetes Cell Therapy Program Encapsulated insulin-producing cell therapy program under the Insulinova joint venture, designed to provide sustained insulin production in vivo for patients with Type 1 and insulin-dependent Type 2 diabetes without requiring immunosuppression.
• Klothonova α-Klotho Longevity Protein Program Encapsulated cell therapy program under the Klothonova joint venture, delivering the α-Klotho longevity protein via encapsulated genetically modified cells to address age-related diseases.
• Klothea Bio License (α-Klotho Therapeutic Program) Licensed α-Klotho therapeutic program out-licensed to Klothea Bio under a one-time license arrangement, providing current revenue to Avaí Bio while Klothea Bio leads development.

Quantifiable outcome

• α-Klotho levels declined ~50% after age 40
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Klothea Bio, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 November 2025Exclusive worldwide license agreement through Klothonova joint venture grants rights to develop, manufacture, and commercialize Klothea Bio's proprietary Klotho-producing cells encapsulated using Cell-in-a-Box® technology. The license covers treatment of diseases and conditions in humans and animals, with milestone payments tied to development and regulatory achievements plus royalties on net sales.
• Insulinova, Inc.coreStrategic or Co-development Partner · 1 November 2025U.S.-based joint venture company between Avaí Bio and SGAustria for developing diabetes treatment using encapsulated insulin-producing cells. The partnership pursues Research Collaboration Agreement to advance proprietary differentiation process converting stem cells into insulin-producing cells for type 1 and insulin-dependent type 2 diabetes therapy.
• Austrianova (SGAustria Pte. Ltd.)coreStrategic or Co-development Partner · 1 September 202550/50 joint venture partner for both Klothonova (α-Klotho therapy) and Insulinova (diabetes treatment). Austrianova provides its proprietary Cell-in-a-Box® cell encapsulation technology, GMP-grade cell products, and cell line development expertise backed by over 50 peer-reviewed publications. The partnership enables Avaí Bio to protect therapeutic cells from immune rejection while enabling continuous protein delivery.
• Klothonova LLCcoreStrategic or Co-development Partner · 1 September 2025Nevada-based 50/50 joint venture between Avaí Bio and Austrianova's affiliate SG Austria Pte. Ltd., established to develop encapsulated cell-based therapies restoring α-Klotho 'longevity protein' levels. The JV combines Avaí Bio's therapeutic focus with Austrianova's cell encapsulation IP and manufacturing capability for age-related conditions including kidney disease, neurodegenerative disorders, and vascular diseases.
• Ainnova Tech, Inc.minorStrategic or Co-development Partner · 1 September 2025Joint venture integrating Ainnova's Vision AI platform for disease detection, including diabetes-related complications, through non-invasive diagnostics. Part of Avaí Bio's ecosystem of joint ventures bridging disease detection and targeted treatment.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sernova Corp: Sernova is developing its Cell Pouch System — an implanted medical device for housing therapeutic cells, including insulin-producing cells for diabetes. It is comparable to Avaí Bio's Insulinova program as a competing cell-based delivery platform for chronic disease.
• ViaCyte: ViaCyte pioneered stem cell-derived encapsulated beta-cell therapies for type 1 diabetes and was acquired by Vertex. Its PEC-Direct and PEC-Qual PEC programs are the most direct predecessors to Avaí Bio's Insulinova program in terms of therapeutic modality and target indication.
• Sigilon Therapeutics: Sigilon developed encapsulated cell therapies (acquired by Eli Lilly in 2023) using a similar protective encapsulation approach to treat diabetes and other conditions. Sigilon is the closest analog to Avaí Bio's Cell-in-a-Box®-based platform in design philosophy.
• CRISPR Therapeutics: CRISPR Therapeutics is partnered with Vertex on the VX-880 gene-edited beta-cell program for T1D, directly competing with Avaí Bio's encapsulated insulin-producing cell approach. CRISPR represents the gene-editing alternative to Avaí Bio's cell encapsulation strategy in the same diabetes indication.

Broad incumbents

• Vertex Pharmaceuticals: Vertex is the most advanced developer of cell therapy for type 1 diabetes (VX-880, partnered with CRISPR Therapeutics), directly competing with Avaí Bio's Insulinova program. With a multi-billion-dollar balance sheet and clinical lead, Vertex is the primary competitive benchmark for the diabetes program.
• Novo Nordisk: Novo Nordisk is the dominant incumbent in insulin and diabetes therapeutics, representing both the standard-of-care benchmark and a potential strategic acquirer for any breakthrough encapsulated insulin-producing cell therapy.
• Eli Lilly: Lilly acquired Sigilon Therapeutics and is a global leader in diabetes therapeutics (Mounjaro, Trulicity). Lilly competes both in the broader diabetes space and in the encapsulated cell therapy subsegment via the Sigilon acquisition.

Emerging players

• ProKidney: ProKidney is a clinical-stage cell therapy company focused on kidney disease, overlapping with one of the named indications in Avaí Bio's α-Klotho program (chronic kidney disease associated with declining Klotho levels).
• Altos Labs: Altos Labs is a well-capitalized longevity biotech focused on cellular rejuvenation programming, directly overlapping with Avaí Bio's α-Klotho longevity protein thesis for age-related disease intervention.
• Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell therapies for neurology, oncology, and chronic disease. Its manufacturing and allogeneic platform parallels Avaí Bio's off-the-shelf encapsulated cell approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AvaiBio
• Facebookfacebook.com/AvaiBio
• LinkedInlinkedin.com/company/avant-technologies-ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avaí Bio